ct

Patent Pick: Spying Secret (Anti)agents

February 15, 2017 | Contact Author | By: Rachel Grabenhofer
Close
Fill out my online form.
  • Article
  • Keywords/Abstract
BeautySpy850

Keywords: Chanel | patent | miRNA | senescence | skin | expression | epigenetics

Abstract: Chanel is on to you, 007, and your silencing effects on miRNA. And in a new patent, the company describes a method to locate agents like you, for your anti-aging skin care benefits. This message will self-destruct in 3, 2, 1. . .

Chanel is spying on skin. In a new patent, the company explains how microRNAs (miRNAs) modulate gene expression in various biological and pathological processes, such as cellular senescence and organism aging.

As such, products or active agents that affect miRNA expression, in turn preventing, reducing or even inhibiting cellular senescence, particularly of the fibroblast, are desired.

A new patent from Chanel discloses a method to identify such agents.

Excerpt Only This is a shortened version or summary of the article you requested. To view the complete article, please log in or create an account. Registration is Free!

Chanel is spying on skin. In a new patent, the company explains how microRNAs (miRNAs) modulate gene expression in various biological and pathological processes, such as cellular senescence and organism aging.

As such, products or active agents that affect miRNA expression, in turn preventing, reducing or even inhibiting cellular senescence, particularly of the fibroblast, are desired. The company's patent discloses a method to identify such agents.

Inhibitors of micro-RNAs for anti-aging benefits in skin
Publication date: Feb. 14, 2017
U.S. Patent 9568467
Assignee: Chanel Parfums Beauté

Disclosed here is an in vitro method for screening candidate compounds for preventing and/or attenuating aging of the skin.

The process involves:

a) bringing at least one test compound into contact with a sample of fibroblasts;

b) measuring the expression or activity of at least one microRNA chosen from miR-134 and miR-152 in said fibroblasts; and

c) selecting the compounds showing at least a 20%, preferably 40% or more, activity in comparison with untreated fibroblasts.

Further details are disclosed in the complete patent listing.